Edition:
India

Biocryst Reports Agreement With PMDA On Phase 3 Clinical Trial of BCX7353 In Japan


Monday, 25 Jun 2018 

June 25 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS AGREEMENT WITH PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY REQUIREMENTS FOR MARKETING AUTHORIZATION OF BCX7353 IN JAPAN.BIOCRYST REPORTS AGREEMENT WITH PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY REQUIREMENTS FOR MARKETING AUTHORIZATION OF BCX7353 IN JAPAN.BIOCRYST PHARMACEUTICALS-AGREEMENT ON DESIGN OF PHASE 3 TRIAL & REGULATORY REQUIREMENTS FOR MARKETING AUTHORIZATION OF BCX7353 FOR HAE WITH PMDA IN JAPAN. 

Company Quote

2.9
0.08 +2.84%
1:30am IST